Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.
By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.
However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks.
AmerisourceBergen is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank.
Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.
Here are three of the most important factors that make the stock of this prescription drug distributor a great growth pick right now.
Earnings Growth
Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for AmerisourceBergen is 12.8%, investors should actually focus on the projected growth. The company's EPS is expected to grow 18.5% this year, crushing the industry average, which calls for EPS growth of 3.8%.
Impressive Asset Utilization Ratio
Growth investors often overlook asset utilization ratio, also known as sales-to-total-assets (S/TA) ratio, but it is an important feature of a real growth stock. This metric exhibits how efficiently a firm is utilizing its assets to generate sales.
Right now, AmerisourceBergen has an S/TA ratio of 4.12, which means that the company gets $4.12 in sales for each dollar in assets. Comparing this to the industry average of 0.83, it can be said that the company is more efficient.
In addition to efficiency in generating sales, sales growth plays an important role. And AmerisourceBergen looks attractive from a sales growth perspective as well. The company's sales are expected to grow 10.9% this year versus the industry average of 2%.
Promising Earnings Estimate Revisions
Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
There have been upward revisions in current-year earnings estimates for AmerisourceBergen. The Zacks Consensus Estimate for the current year has surged 0.4% over the past month.
Bottom Line
While the overall earnings estimate revisions have made AmerisourceBergen a Zacks Rank #2 stock, it has earned itself a Growth Score of A based on a number of factors, including the ones discussed above.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
This combination positions AmerisourceBergen well for outperformance, so growth investors may want to bet on it.
Image: Bigstock
Is AmerisourceBergen (ABC) a Solid Growth Stock? 3 Reasons to Think "Yes"
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.
By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.
However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks.
AmerisourceBergen is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank.
Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.
Here are three of the most important factors that make the stock of this prescription drug distributor a great growth pick right now.
Earnings Growth
Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for AmerisourceBergen is 12.8%, investors should actually focus on the projected growth. The company's EPS is expected to grow 18.5% this year, crushing the industry average, which calls for EPS growth of 3.8%.
Impressive Asset Utilization Ratio
Growth investors often overlook asset utilization ratio, also known as sales-to-total-assets (S/TA) ratio, but it is an important feature of a real growth stock. This metric exhibits how efficiently a firm is utilizing its assets to generate sales.
Right now, AmerisourceBergen has an S/TA ratio of 4.12, which means that the company gets $4.12 in sales for each dollar in assets. Comparing this to the industry average of 0.83, it can be said that the company is more efficient.
In addition to efficiency in generating sales, sales growth plays an important role. And AmerisourceBergen looks attractive from a sales growth perspective as well. The company's sales are expected to grow 10.9% this year versus the industry average of 2%.
Promising Earnings Estimate Revisions
Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
There have been upward revisions in current-year earnings estimates for AmerisourceBergen. The Zacks Consensus Estimate for the current year has surged 0.4% over the past month.
Bottom Line
While the overall earnings estimate revisions have made AmerisourceBergen a Zacks Rank #2 stock, it has earned itself a Growth Score of A based on a number of factors, including the ones discussed above.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
This combination positions AmerisourceBergen well for outperformance, so growth investors may want to bet on it.